08:05 AM EDT, 08/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our target price to USD51 (from USD44) as we raise our 2025 EPS estimate to USD2.34 (from USD2.30) and 2026 estimate to USD2.60 (from USD2.54) in view of the latest result. This implies a 2025 P/E of 22x, in line with its historical average. Given the H1 2025 performance and considering current macroeconomic trends (including the U.S. and China import tariffs), Qiagen ( QGEN ) upgraded its 2025 sales growth outlook while the guidance for adjusted EPS (which was raised in April) remained unchanged. We are encouraged by Qiagen's ( QGEN ) continued strong performance, with the Diagnostic Solutions segment expected to remain the main growth contributor. We expect QuantiFERON (+13% CER in H1) and QIAstat-Dx (+39% CER in H1) to continue fueling growth. The initiation of its first-ever dividend in 2025 adds to the stock's appeal, in our view, though ongoing macroeconomic uncertainty, particularly relating to tariffs, remains a risk.